The latest price target for IGC Pharma (AMEX:IGC) was reported by Ascendiant Capital on September 3, 2024. The analyst firm set a price target for $3.75 expecting IGC to fall to within 12 months (a possible NaN% downside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for IGC Pharma (AMEX:IGC) was provided by Ascendiant Capital, and IGC Pharma maintained their buy rating.

There is no last upgrade for IGC Pharma

There is no last downgrade for IGC Pharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of IGC Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for IGC Pharma was filed on September 3, 2024 so you should expect the next rating to be made available sometime around September 3, 2025.

While ratings are subjective and will change, the latest IGC Pharma (IGC) rating was a maintained with a price target of $3.50 to $3.75. The current price IGC Pharma (IGC) is trading at is $undefined, which is out of the analyst’s predicted range.